The GCIPL deviation frequency map demonstrating the topographic relationship between pRNFL and GCIPL defects was generated using SD-OCT. Our results indicated the topographic location of retinal ganglion cell death associated with clock-hour location of pRNFL loss in vivo.
ABSTRACT.Purpose: To evaluate the ability of the deviation map of macular ganglion cellinner plexiform layer (GCIPL) thickness compared with that of peripapillary retinal nerve fibre layer (pRNFL) thickness for detection of localized RNFL defects shown on red-free RNFL photography. Methods: This prospective cross-sectional study included 69 eyes of 69 subjects with preperimetric or perimetric glaucoma (mean deviation (MD) >À12dB) and localized RNFL defects along with 79 eyes of 79 normal control subjects. The number of abnormal superpixels on the both macular GCIPL and pRNFL deviation maps by Cirrus OCT corresponding to localized RNFL defects was calculated using a customized Matlab program and presented as severity indices according to each of the probability levels. The areas under the receiver operating characteristic curves (AUROCs) of the severity indices were compared between the two deviation maps. Results: According to three criteria and corresponding probability levels, the AUROCs of the GCIPL and pRNFL deviation maps ranged from 0.910 to 0.931 and 0.934 to 0.950, respectively. However, the differences were not statistically significant (all p > 0.05). Significant correlations were observed between the severity indices of the GCIPL deviation map and those of the pRNFL deviation map, regardless of the criteria (all p < 0.0001). Conclusions: In the detection of glaucomatous eyes with localized RNFL defects, the macular GCIPL thickness deviation map showed a level of diagnostic performance comparable to that of the pRNFL thickness deviation map.
In POAG eyes, DH was larger in area and longer in length in cases of normal-baseline IOP than in cases of high-baseline IOP. This suggests the possibility that previous studies' findings of higher DH prevalence and incidence in normal-baseline IOP-POAG eyes were partially affected by these topographic characteristics, which make DH more easily detectable.
BackgroundThe purpose of this study was to investigate the association of a novel biometric parameter, relative lens vault (LV), with primary angle-closure (PAC) and primary angle-closure glaucoma (PACG).MethodsWe evaluated 101 subjects with PAC (G) and 101 normal subjects that were age- and gender-matched. Based on anterior-segment optical coherence tomography scans, and using customized software, the anterior vault (AV) and LV were measured. They were defined as the maximum distances between the horizontal line connecting the two scleral spurs and the posterior corneal surface and anterior lens surface, respectively. The relative LV was calculated by dividing the LV by the AV.ResultsSignificant differences between PAC (G) eyes and normal eyes were found in the LV (1.06 ± 0.41 vs. 0.36 ± 0.37 mm, P < 0.001), relative LV (0.34 ± 0.23 vs. 0.11 ± 0.25, P < 0.001), and axial length (22.96 ± 0.94 vs. 24.02 ± 1.33 mm, P < 0.001). However, the two groups’ values of the AV relative to those of axial length were quite similar (both 0.14 ± 0.03, P = 0.91). The relative LV values distinguished between PAC (G) eyes and normal eyes better than the LV values (area under the receiver operator characteristic curve: 0.97 vs. 0.92, P = 0.032).ConclusionsOur results suggest that relative dimensions of the eyeball’s anterior portion in PAC (G) eyes might be within the normal range. And the value of LV relative to that of the AV (i.e., the relative LV) is more closely related to PAC (G) than is the absolute value of LV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.